Rna Diagnostics Inc., a Canadian company with a patented platform technology providing real-time cancer therapy guidance, announced today the closing of a $5 million Series A financing. The funding was led by iGAN Partners and includes new and existing investors.
Rna Diagnostics’ platform technology is the RNA Disruption Assay™ (RDA). RDA is a diagnostic test that measures tumor response after the 1st cycle (14–21 days) of neoadjuvant therapy (drug treatment prior to surgery). It is expected to become a critical tool for managing response-guided therapy in cancer patients. RDA consists of proprietary methods that quantify and score the degradation (disruption) of ribosomal RNA (rRNA) within tumors induced by response to a wide spectrum of chemotherapeutic and targeted drugs. RNA disruption has been shown to be an effective predictor of response/non-response and survival after neoadjuvant therapy.